Key Points
- CRSP declined by as much as 11.59% during Friday’s session, reaching an intraday low of $51.21
- First quarter results disappointed: EPS posted at -$1.37 compared to analyst expectations of -$1.15; revenue totaled $0.86M versus forecasts of $4.72M — a year-over-year decline of 97.8%
- Regeneron received approval for Otarmeni, a gene therapy that will be provided at no cost to qualifying U.S. patients, creating competitive concerns around Casgevy’s pricing strategy
- Chief Executive Samarth Kulkarni divested 10,349 shares on March 16; company insiders collectively sold 51,828 shares during the previous three months
- Wall Street maintains a consensus “Moderate Buy” rating with a mean price target of $64.53
CRISPR Therapeutics ($CRSP) experienced a challenging Friday session. Shares tumbled by as much as 11.59%, touching an intraday bottom of $51.21, before closing near $51.04 — a significant retreat from the previous session’s close of $55.18. Trading volume reached approximately 1.36 million shares, running about 27% lighter than typical activity.
The sharp decline stemmed from a confluence of two negative catalysts: disappointing quarterly results and emerging competition from Regeneron’s pricing strategy.
Regarding financial performance, CRISPR delivered earnings per share of -$1.37 for the period, falling short of the -$1.15 consensus forecast. Revenue registered at merely $0.86 million — substantially below the anticipated $4.72 million. This represents a dramatic 97.8% contraction compared to the same quarter last year, surprising market participants.
The biotechnology firm’s return on equity currently stands at -26.31%, while operating with a substantially negative net margin. Wall Street analysts project full-year EPS of -$4.93.
Regeneron’s Zero-Cost Gene Therapy Creates Market Disruption
The second major development involves Regeneron’s recent regulatory success. The pharmaceutical company secured approval for Otarmeni, a gene therapy that will be distributed without charge to qualifying U.S. patients. This pricing approach represents a significant challenge to the gene-editing industry’s traditional economic model.
CRISPR’s primary commercial product, Casgevy — co-developed alongside Vertex Pharmaceuticals — carries a list price of $2.2 million per patient. Market observers worry that Regeneron’s zero-cost distribution model may reshape pricing expectations throughout the sector, potentially undermining the value proposition for high-priced, single-administration treatments.
Casgevy achieved historical significance as the first CRISPR-based therapy to receive FDA approval, marking a watershed moment for the technology. However, commercial adoption has progressed more slowly than initially anticipated, and Regeneron’s announcement introduces additional complexity to the revenue outlook.
Executive Stock Disposals Create Additional Headwinds
Insider transaction patterns have contributed to investor apprehension. Chief Executive Samarth Kulkarni disposed of 10,349 shares on March 16 at an average price of $48.26, trimming his holdings by approximately 4%. General Counsel James Kasinger sold 3,450 shares during the same timeframe.
During the preceding three-month period, company insiders collectively divested 51,828 shares, generating proceeds of roughly $2.58 million. Insider ownership currently represents 4.30% of outstanding shares.
While such transactions are relatively common among biotech executives managing equity-based compensation packages, the timing contributes to prevailing caution surrounding the stock.
Analyst perspectives vary while maintaining a generally optimistic tilt. Bank of America assigns a Buy rating with an $89 price objective. Needham maintains a Buy rating with an $82 target. TD Cowen holds a Hold rating with a $45 projection. Citizens JMP rates the stock Market Outperform with an $80 target. The aggregate consensus stands at Moderate Buy, with an average price target of $64.53 — representing significant upside from current trading levels.
The stock’s 50-day moving average registers at $52.68 while the 200-day moving average sits at $55.70. Market capitalization currently approximates $4.90 billion with a beta coefficient of 1.80.
Current price action shows CRSP trading around $51, positioned below both significant moving average benchmarks.
